Answer
Donanemab is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.
Sources for this answer
- Kisunla 350 mg concentrate for solution for infusionEli Lilly and Company Limited · emc · SmPC §4.1 Therapeutic Indications · Version 3Document updated
Sources checked